home / stock / apli:cc / apli:cc news

APLI:CC News and Press, Appili Therapeutics Inc. From 08/11/23

Stock Information
Company Name: Appili Therapeutics Inc.
Stock Symbol: APLI:CC
Market: TSXC
Website: appilitherapeutics.com
Menu
APLI:CC APLI:CC Quote APLI:CC Short APLI:CC News APLI:CC Articles APLI:CC Message Board
Get APLI:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
APLI:CC - Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

FDA established a PDUFA action date for ATI-1501 of September 23, 2023 Government funding committed to enable Appili to advance its biodefense vaccine candidate ATI-1701 towards an IND Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appi...
APLI:CC - Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...

APLI:CC - Appili Therapeutics - Press Release Correction

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), announced today a correction to its press release entitled “Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results” which was issued on June 23, 2023 (t...

APLI:CC - Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

Executed US$7.3M initial contract with U.S. Air Force Academy for ATI-1701 Upcoming PDUFA date of September 23, 2023 for ATI-1501 Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on dru...
APLI:CC - Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

Upcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Pat...

APLI:CC - Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy

Funding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “...

APLI:CC - Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will presen...
APLI:CC - Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications Dr. Nabors representing Appili at the World Vaccine Congress in Washington, D.C. Appili Therapeutics Inc. (TSX: AP...

APLI:CC - Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectiou...

APLI:CC - Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal yea...
Previous 10 Next 10